Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.

Authors

null

Frederic Pouliot

Laval University and CHU De Quebec, Quebec, QC, Canada

Frederic Pouliot , Fred Saad , Patrick O. Richard , Stephan Probst , Étienne Rousseau , Eric Levesque , Vincent Castonguay , Nicolas Marcoux , Michele Lodde , Jean-Baptiste Lattouf , François-Alexandre Buteau , Daniel Juneau , Zineb Hamilou , Michel Pavic , Jean-Francois Castilloux , Atefeh Zamanian , Guillaume Bouvet , Amelie Tetu , Brigitte Guérin , Jean-Mathieu Beauregard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Clinical Trial Registration Number

NCT04000776

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5033)

DOI

10.1200/JCO.2023.41.16_suppl.5033

Abstract #

5033

Poster Bd #

127

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Genitourinary Cancers Symposium

Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.

Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.

First Author: Ahmed M. Mahmoud

Poster

2024 ASCO Genitourinary Cancers Symposium

Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Frederic Pouliot

Poster

2024 ASCO Genitourinary Cancers Symposium

SABRE: Assessment of safety and efficacy of <sup>64</sup>Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.

SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.

First Author: Luke T. Nordquist